Related Experiment Video
Updated: Jan 8, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
Chiglitazar, a PPAR pan-agonist: Impacts on type 2 diabetes mellitus and multi-system metabolic regulation - A review
Ee Chang1, Yiran Zhu1, Wei Wei1
1Department of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China; The First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, China.
Abstract:
Type 2 diabetes mellitus (T2DM) is a prevalent chronic metabolic disorder with multifactorial pathogenesis involving genetic predisposition, environmental influences, and dietary habits. Insulin resistance represents a central pathophysiological mechanism. Current evidence suggests that peroxisome proliferator-activated receptors (PPARs)-including PPARα, PPARδ, and PPARγ-can effectively ameliorate insulin resistance and associated metabolic syndromes; however, overstimulation of a single receptor subtype may lead to adverse effects. As a novel pan-PPAR agonist, chiglitazar achieves balanced activation of all three PPAR subtypes, providing significant glycemic control while exhibiting potential therapeutic benefits for metabolic-associated steatohepatitis (MASH), dyslipidemia, and other metabolism-related systemic disorders, thereby demonstrating superior metabolic regulatory properties. This review examines the interplay between T2DM and PPARs, explores the pharmacological mechanisms, clinical efficacy, and safety profile of chiglitazar, and highlights its multi-system metabolic benefits beyond glycemic control. These findings provide theoretical and practical insights supporting its clinical application in T2DM and related metabolic disorders.
More Related Videos
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...